| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1056/NEJM200105033441807 |
| P698 | PubMed publication ID | 11333996 |
| P2093 | author name string | Stephens DS | |
| Popovic T | |||
| Hughes JM | |||
| Perkins BA | |||
| Rosenstein NE | |||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1378-1388 | |
| P577 | publication date | 2001-05-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Meningococcal disease. | |
| P478 | volume | 344 |
| Q39695303 | 5' exonuclease assay for detection of serogroup Y Neisseria meningitidis |
| Q37263960 | A High-Throughput Size Exclusion Chromatography Method to Determine the Molecular Size Distribution of Meningococcal Polysaccharide Vaccine. |
| Q33939014 | A Licensed Combined Haemophilus influenzae Type b-Serogroups C and Y Meningococcal Conjugate Vaccine. |
| Q37192100 | A case of meningococcal sepsis and meningitis with complement 7 deficiency in a military trainee |
| Q36399953 | A chromosomally integrated bacteriophage in invasive meningococci |
| Q41866812 | A computational genomics pipeline for prokaryotic sequencing projects |
| Q34972731 | A decade of invasive meningococcal disease surveillance in Poland. |
| Q84840768 | A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children |
| Q59567082 | A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease |
| Q36314792 | A functional two-partner secretion system contributes to adhesion of Neisseria meningitidis to epithelial cells |
| Q60953575 | A new meningococcal B vaccine for adolescents and adults: characteristics and methods of use |
| Q51969880 | A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants. |
| Q33521253 | A novel phase variation mechanism in the meningococcus driven by a ligand-responsive repressor and differential spacing of distal promoter elements |
| Q40168841 | A pain in the joints |
| Q77549321 | A plethora of host factors that determine the outcome of meningococcal infection |
| Q44257285 | A space-time conditional intensity model for invasive meningococcal disease occurrence |
| Q60469224 | A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix® in subjects aged 11–17 years: An open, randomised, controlled trial |
| Q41433426 | A very rare case of primary meningococcal arthritis in an adult male |
| Q38680833 | A virulence-associated filamentous bacteriophage of Neisseria meningitidis increases host-cell colonisation. |
| Q34396376 | Absence of Neisseria meningitidis W-135 electrophoretic Type 37 during the Hajj, 2002. |
| Q33902502 | Acquisition of W135 meningococcal carriage in Hajj pilgrims and transmission to household contacts: prospective study |
| Q53685199 | Acquisition of virulence genes by a carrier strain gave rise to the ongoing epidemics of meningococcal disease in West Africa. |
| Q37945754 | Acute bacterial meningitis in infants and children: epidemiology and management |
| Q35689237 | Affinity-purified human immunoglobulin G that binds a lacto-N-neotetraose-dependent lipooligosaccharide structure is bactericidal for serogroup B Neisseria meningitidis. |
| Q47231460 | An epidemic of meningococcal disease in children in North Norway in the 1970s and 1980s was dominated by a hypervirulent group B strain |
| Q33850814 | An epidemiological review of changes in meningococcal biology during the last 100 years |
| Q83656070 | An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children |
| Q24806018 | An unusual case of chronic meningitis |
| Q33184132 | Analysis of pathogen-host cell interactions in purpura fulminans: expression of capsule, type IV pili, and PorA by Neisseria meningitidis in vivo. |
| Q34033132 | Anti-idiotypic antibody as a potential candidate vaccine for Neisseria meningitidis serogroup B. |
| Q24202905 | Antibiotics for preventing meningococcal infections |
| Q24235036 | Antibiotics for preventing meningococcal infections |
| Q24243847 | Antibiotics for preventing meningococcal infections |
| Q39319258 | Antibodies directed to Neisseria gonorrhoeae impair nerve growth factor-dependent neurite outgrowth in Rat PC12 cells |
| Q37713775 | Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents |
| Q37130274 | Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine |
| Q36227917 | Antiidiotypic DNA vaccination induces serum bactericidal activity and protection against group B meningococci |
| Q47356918 | Application of camelid heavy-chain variable domains (VHHs) in prevention and treatment of bacterial and viral infections. |
| Q81107962 | Applying a case-crossover study design to examine transient exposures in the transmission of N. meningitidis |
| Q35976434 | Applying the bacterial meningitis score in children with cerebrospinal fluid pleocytosis: a single center's experience. |
| Q58663801 | Are there characteristics of infectious diseases that raise special ethical issues? |
| Q35901353 | Assessing the economics of vaccination for Neisseria meningitidis in industrialized nations: a review and recommendations for further research |
| Q43992230 | Assessment of vaccine potential of the Neisseria-specific protein NMB0938. |
| Q92156626 | Atypical, Yet Not Infrequent, Infections with Neisseria Species |
| Q42234518 | Avidity of IgG antibodies against meningococcal serogroup a polysaccharide and correlations with bactericidal activity in sera from meningitis patients and controls from Ethiopia |
| Q41944376 | Bacteraemic pneumonia caused by Neisseria meningitidis serogroup Y. |
| Q35714421 | Bacteremia in an immunocompromised patient caused by a commensal Neisseria meningitidis strain harboring the capsule null locus (cnl). |
| Q63367687 | Bacterial meningitis |
| Q93157098 | Bacterial meningitis in Sudanese children; critical evaluation of the clinical decision using clinical prediction rules |
| Q24798186 | Bench-to-bedside review: genetic influences on meningococcal disease |
| Q34562726 | Bexsero® chronicle |
| Q40131360 | Biochemical and biophysical characterization of the sialyl-/hexosyltransferase synthesizing the meningococcal serogroup W135 heteropolysaccharide capsule |
| Q37727051 | Biofilm formation by the human pathogen Neisseria meningitidis |
| Q34983505 | Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis |
| Q38591053 | Bivalent rLP2086 Vaccine (Trumenba(®)): A Review in Active Immunization Against Invasive Meningococcal Group B Disease in Individuals Aged 10-25 Years |
| Q30240302 | Burden of Neisseria meningitidis infections in China: a systematic review and meta-analysis |
| Q38011316 | Can we, should we, eradicate the meningococcus? |
| Q59244167 | Capsule null locus meningococci: Typing of antigens used in an investigational multicomponent meningococcus serogroup B vaccine |
| Q37929754 | Carriage of Neisseria meningitidis in Europe: a review of studies undertaken in the region |
| Q39121283 | Carriage rates of Neisseria meningitidis serogroups: determination among freshmen conscripts before vaccination |
| Q37857251 | Challenges for development of meningococcal vaccines in infants and children. |
| Q40823410 | Changing epidemiology of Infant Meningococcal Disease after the introduction of meningococcal serogroup C vaccine in Italy, 2006-2014. |
| Q80585599 | Changing epidemiology of bacterial meningitis |
| Q82470543 | Changing the diagnostic framework of meningococcal disease |
| Q35998399 | Characterisation of the Immunomodulatory Effects of Meningococcal Opa Proteins on Human Peripheral Blood Mononuclear Cells and CD4+ T Cells. |
| Q43490036 | Characteristics of Neisseria meningitidis isolates causing fatal disease |
| Q30248749 | Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®). |
| Q51972357 | Characterization and immunogenicity of meningococcal group C conjugate vaccine prepared using hydrazide-activated tetanus toxoid. |
| Q50857953 | Characterization of ST-4821 complex, a unique Neisseria meningitidis clone. |
| Q48077589 | Characterization of a new Neisseria meningitidis serogroup C clone from China |
| Q89807070 | Characterization of a transcriptional TPP riboswitch in the human pathogen Neisseria meningitidis |
| Q58800725 | Characterization of capsule genes in non-pathogenic Neisseria species |
| Q34529441 | Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies |
| Q41012990 | Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine |
| Q36407498 | Characterization of invasive Neisseria meningitidis from Atlantic Canada, 2009 to 2013: With special reference to the nonpolysaccharide vaccine targets (PorA, factor H binding protein, Neisseria heparin-binding antigen and Neisseria adhesin A). |
| Q90565601 | Characterization of invasive Neisseria meningitidis isolates recovered from children in Turkey during a period of increased serogroup B disease, 2013-2017 |
| Q35708801 | Characterization of invasive Neisseria meningitidis strains from Québec, Canada, during a period of increased serogroup B disease, 2009-2013: phenotyping and genotyping with special emphasis on the non-carbohydrate protein vaccine targets |
| Q37021368 | Characterization of serogroup A Neisseria meningitidis from invasive meningococcal disease cases in Canada between 1979 and 2006: Epidemiological links to returning travellers |
| Q58796292 | Characterization of strains of Neisseria meningitidis causing meningococcal meningitis in Mozambique, 2014: Implications for vaccination against meningococcal meningitis |
| Q36421826 | Characterizing non-hydrolyzing Neisseria meningitidis serogroup A UDP-N-acetylglucosamine (UDP-GlcNAc) 2-epimerase using UDP-N-acetylmannosamine (UDP-ManNAc) and derivatives |
| Q38444590 | Chemoprophylaxis and vaccination in preventing subsequent cases of meningococcal disease in household contacts of a case of meningococcal disease: a systematic review. |
| Q40508835 | Chronic meningococcemia |
| Q61801196 | Chronic meningococcemia |
| Q90137827 | Chronic meningococcemia: a rare presentation of meningococcal disease: case report |
| Q57810209 | Chronic meningococcemia: a report of 26 cases and literature review |
| Q40617364 | Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso |
| Q38402991 | Ciprofloxacin-resistant Neisseria meningitidis in Canada: likely imported strains |
| Q35901833 | Climate Regimes, El Niño-Southern Oscillation, and Meningococcal Meningitis Epidemics |
| Q40212289 | Clinical presentation of invasive disease caused by Neisseria meningitidis serogroup Y in Sweden, 1995 to 2012. |
| Q82470641 | Clinical recognition of meningococcal disease in children and adolescents |
| Q54324377 | Clinically based surveillance of invasive meningococcal disease in young children admitted to selected US hospitals between January 2000 and June 2009: a retrospective cohort study. |
| Q36363154 | Clonal analysis of Neisseria meningitidis serogroup B strains in South Africa, 2002 to 2006: emergence of new clone ST-4240/6688. |
| Q33704817 | Clonal distribution of disease-associated and healthy carrier isolates of Neisseria meningitidis between 1983 and 2005 in Cuba |
| Q43865671 | Combined antithrombin and protein C supplementation in meningococcal purpura fulminans: a pharmacokinetic study |
| Q92738754 | Comparison of Immune Responses to Two Quadrivalent Meningococcal Conjugate Vaccines (CRM197 and Diphtheria Toxoid) in Healthy Adults |
| Q36434366 | Comparison of Phenotypic and Genotypic Approaches to Capsule Typing of Neisseria meningitidis by Use of Invasive and Carriage Isolate Collections |
| Q37600163 | Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10-25 Years of Age. |
| Q40257069 | Comparison of the inflammatory response of brain microvascular and peripheral endothelial cells following infection with Neisseria meningitidis |
| Q59392341 | Compartmental models for seasonal hyperendemic bacterial meningitis in the African meningitis belt |
| Q48181626 | Complement C5a Receptor 1 Exacerbates the Pathophysiology of N. meningitidis Sepsis and Is a Potential Target for Disease Treatment. |
| Q57167390 | Complement and Bacterial Infections: From Molecular Mechanisms to Therapeutic Applications |
| Q33584672 | Complete Genome Sequence of Neisseria meningitidis Serogroup A Strain NMA510612, Isolated from a Patient with Bacterial Meningitis in China |
| Q30164390 | Conformational epitopes recognized by protective anti-neisserial surface protein A antibodies |
| Q58504174 | Conjoint Analysis of French and German Parents??? Willingness to Pay for Meningococcal Vaccine |
| Q38367830 | Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience |
| Q34516060 | Construction of Opa-positive and Opa-negative strains of Neisseria meningitidis to evaluate a novel meningococcal vaccine |
| Q90678860 | Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults |
| Q40595860 | Cost-benefit model comparing two alternative immunisation programmes against serogroup C meningococcal disease: for Quebec residents aged 2 months to 20 years |
| Q35187182 | Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive disease |
| Q33613839 | Critical roles of complement and antibodies in host defense mechanisms against Neisseria meningitidis as revealed by human complement genetic deficiencies |
| Q50577810 | Crowding as a risk factor of meningococcal disease in Danish preschool children: a nationwide population-based case-control study. |
| Q27675346 | Crystal Structure of Outer Membrane Protein NMB0315 from Neisseria meningitidis |
| Q41912569 | Crystal structures of human Fabs targeting the Bexsero meningococcal vaccine antigen NHBA |
| Q42030226 | Crystallization and preliminary X-ray analysis of CrgA, a LysR-type transcriptional regulator from pathogenic Neisseria meningitidis MC58 |
| Q42124015 | Crystallization and preliminary crystallographic characterization of the iron-regulated outer membrane lipoprotein FrpD from Neisseria meningitidis |
| Q64099622 | Culture and Real-time Polymerase Chain reaction sensitivity in the diagnosis of invasive meningococcal disease: Does culture miss less severe cases? |
| Q35539716 | Current immunizations for travel |
| Q28903782 | Cytosolic proteins contribute to surface plasminogen recruitment of Neisseria meningitidis |
| Q31119743 | Deadly viral syndrome mimics |
| Q26741975 | Deciphering the Burden of Meningococcal Disease: Conventional and Under-recognized Elements |
| Q33440465 | Delayed recognition of fatal invasive meningococcal disease in adults |
| Q34983112 | Development and evaluation of a dipstick diagnostic test for Neisseria meningitidis serogroup X |
| Q35668204 | Development of a multiplex PCR assay for detection and genogrouping of Neisseria meningitidis |
| Q91966792 | Difference in virulence between Neisseria meningitidis serogroups W and Y in transgenic mice |
| Q43083529 | Differences in the population structure of Neisseria meningitidis in two Australian states: Victoria and Western Australia |
| Q34634162 | Dissection of hexosyl- and sialyltransferase domains in the bifunctional capsule polymerases from Neisseria meningitidis W and Y defines a new sialyltransferase family |
| Q34916886 | Distinct binding and immunogenic properties of the gonococcal homologue of meningococcal factor h binding protein |
| Q52332492 | Distinct evolutionary patterns of Neisseria meningitidis serogroup B disease outbreaks at two universities in the USA. |
| Q91631671 | Distinct roles of the anaphylatoxin receptors C3aR, C5aR1 and C5aR2 in experimental meningococcal infections |
| Q37597599 | Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway |
| Q43624944 | Distribution of serogroups and sequence types in disease-associated and carrier strains of Neisseria meningitidis isolated in China between 2003 and 2008. |
| Q34513606 | Distribution of the type III DNA methyltransferases modA, modB and modD among Neisseria meningitidis genotypes: implications for gene regulation and virulence. |
| Q33330135 | Distribution of transferrin binding protein B gene (tbpB) variants among Neisseria species |
| Q24810495 | Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies |
| Q44536708 | Dynamics of childhood invasive meningococcal disease in Israel during a 22-year period (1989-2010). |
| Q43932679 | Effectiveness of a trivalent serogroup A/C/W135 meningococcal polysaccharide vaccine in Burkina Faso, 2003. |
| Q38128112 | Effectiveness of meningococcal serogroup C vaccine programmes |
| Q42363077 | Emergence and genomic diversification of a virulent serogroup W:ST-2881(CC175) Neisseria meningitidis clone in the African meningitis belt |
| Q46242483 | Emergence of endemic serogroup W135 meningococcal disease associated with a high mortality rate in South Africa |
| Q40509039 | Emergence of meningococci with reduced susceptibility to third-generation cephalosporins |
| Q34401684 | Emergence of serogroup C meningococcal disease associated with a high mortality rate in Hefei, China |
| Q37756378 | Emergency dermatopathology. |
| Q36743337 | Emergency diagnosis and treatment of adult meningitis |
| Q52340790 | Enhancement of drug permeability across blood brain barrier using nanoparticles in meningitis. |
| Q37092409 | Environmental exposures and invasive meningococcal disease: an evaluation of effects on varying time scales. |
| Q36791114 | EpiScanGIS: an online geographic surveillance system for meningococcal disease |
| Q34017750 | Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution |
| Q34644525 | Epidemic meningitis, meningococcaemia, and Neisseria meningitidis |
| Q40173724 | Epidemiological Effectiveness and Cost of a Fungal Meningitis Outbreak Response in New River Valley, Virginia: Local Health Department and Clinical Perspectives |
| Q36131880 | Epidemiological and Molecular Characterization of Invasive Meningococcal Disease in Italy, 2008/09-2012/13. |
| Q37761235 | Epidemiology and meningococcal serogroup distribution in the United States |
| Q43955969 | Epidemiology of invasive meningococcal disease in Austria 2010. |
| Q33676419 | Epidemiology of invasive meningococcal disease with decreased susceptibility to penicillin in Ontario, Canada, 2000 to 2006 |
| Q37734624 | Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention. |
| Q34219135 | Epidemiology of meningococcal disease, New York City, 1989-2000. |
| Q37272815 | Epidemiology of pathogenic Neisseria meningitidis serogroup B serosubtypes in Malta: implications for introducing PorA based vaccines. |
| Q43753962 | Epidemiology of purpura fulminans and early therapeutic recommendations |
| Q34396428 | Epidemiology of serogroup B invasive meningococcal disease in Ontario, Canada, 2000 to 2010. |
| Q33939565 | Epidemiology, molecular characterization and antibiotic resistance of Neisseria meningitidis from patients ≤15 years in Manhiça, rural Mozambique |
| Q36100035 | Epitope Mapping of a Monoclonal Antibody Directed against Neisserial Heparin Binding Antigen Using Next Generation Sequencing of Antigen-Specific Libraries |
| Q38298541 | Epitope specificities of the group Y and W-135 polysaccharides of Neisseria meningitidis |
| Q31155603 | Epitopes recognized by a nonautoreactive murine anti-N-propionyl meningococcal group B polysaccharide monoclonal antibody |
| Q26770711 | Estimates of the burden of meningococcal disease in Italy: implications for prevention and control |
| Q34458576 | Estimating costs associated with a community outbreak of meningococcal disease in a colombian Caribbean city. |
| Q90494296 | Evaluation of Neisseria meningitidis Carriage with the Analysis of Serogroups, Genogroups and Clonal Complexes among Polish Soldiers |
| Q50544809 | Evaluation of a University-Based Mandatory Vaccine Program. |
| Q47445185 | Evaluation of non-culture diagnosis of invasive meningococcal disease by polymerase chain reaction (PCR) |
| Q43801521 | Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model |
| Q52005197 | Evidence for Naturally Acquired T Cell-Mediated Mucosal Immunity to Neisseria meningitidis |
| Q36014181 | Evolutionary Events Associated with an Outbreak of Meningococcal Disease in Men Who Have Sex with Men. |
| Q35157950 | Exonic single nucleotide polymorphisms within TLR3 associated with infant responses to serogroup C meningococcal conjugate vaccine |
| Q37503239 | Expanding prevention of invasive meningococcal disease |
| Q36600323 | Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135. |
| Q33979760 | Experimental meningococcal sepsis in congenic transgenic mice expressing human transferrin |
| Q33614888 | Expression of factor H binding protein of meningococcus responds to oxygen limitation through a dedicated FNR-regulated promoter. |
| Q41307878 | Expression of phosphofructokinase in Neisseria meningitidis |
| Q90179453 | Extensive Changes in Transcriptomic "Fingerprints" and Immunological Cells in the Large Organs of Patients Dying of Acute Septic Shock and Multiple Organ Failure Caused by Neisseria meningitidis |
| Q40541746 | Extra-meningeal meningococcal infection: report of 14 cases |
| Q41825787 | Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. |
| Q28828544 | Factors contributing to the immunogenicity of meningococcal conjugate vaccines |
| Q36065267 | Fast and accurate dynamic estimation of field effectiveness of meningococcal vaccines |
| Q35637960 | Fatal acute cellulitis due to Neisseria meningitidis |
| Q41779897 | Fatal meningococcemia |
| Q79223728 | Fever and rash |
| Q55021359 | Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults. |
| Q41911974 | Frequency and rate of pilin antigenic variation of Neisseria meningitidis |
| Q36850638 | Fully Synthetic Self-Adjuvanting α-2,9-Oligosialic Acid Based Conjugate Vaccines against Group C Meningitis |
| Q48438627 | Fulminant meningococcal sepsis in a woman with previously unknown hyposplenism. |
| Q33557973 | Functional characterization of Lpt3 and Lpt6, the inner-core lipooligosaccharide phosphoethanolamine transferases from Neisseria meningitidis |
| Q42287840 | Functional impacts of the diversity of the meningococcal factor H binding protein |
| Q35913820 | Genetic and antigenic analysis of invasive serogroup Y Neisseria meningitidis isolates collected from 1999 to 2003 in Canada |
| Q54573072 | Genetic polymorphism of the binding domain of surfactant protein-A2 increases susceptibility to meningococcal disease. |
| Q34119434 | Genetic study of capsular switching between Neisseria meningitidis sequence type 7 serogroup A and C strains |
| Q35757635 | Genome-Based Characterization of Emergent Invasive Neisseria meningitidis Serogroup Y Isolates in Sweden from 1995 to 2012. |
| Q42614141 | Genomic basis of a polyagglutinating isolate of Neisseria meningitidis |
| Q43717706 | Genotypic analysis of serogroups other than A, B or C of Neisseria meningitidis in China |
| Q52648036 | Genotypic and phenotypic characterization of the O-linked protein glycosylation system reveals high glycan diversity in paired meningococcal carriage isolates. |
| Q44677055 | Global epidemiology of meningococcal disease. |
| Q54233532 | Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines. |
| Q35624257 | Global transcriptome analysis reveals small RNAs affecting Neisseria meningitidis bacteremia. |
| Q51672415 | Gram-negative Diplococcal Respiratory Infections. |
| Q89786345 | Health workers' perceptions and challenges in implementing meningococcal serogroup a conjugate vaccine in the routine childhood immunization schedule in Burkina Faso |
| Q38386703 | HexR Controls Glucose-Responsive Genes and Central Carbon Metabolism in Neisseria meningitidis |
| Q38011311 | History of meningococcal vaccines and their serological correlates of protection |
| Q53154921 | Hospital costs, length of stay and mortality associated with childhood, adolescent and young adult meningococcal disease in the US. |
| Q36094265 | Hospital-based surveillance of meningococcal meningitis in Salvador, Brazil |
| Q58786438 | Hospitalization rates and outcome of invasive bacterial vaccine-preventable diseases in Tuscany: a historical cohort study of the 2000-2016 period |
| Q37335682 | Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis |
| Q37718321 | Host genetics and outcome in meningococcal disease: a systematic review and meta-analysis |
| Q35917294 | Host response to Neisseria meningitidis lacking lipopolysaccharides |
| Q28077430 | Host-pathogen interactions in bacterial meningitis |
| Q28597911 | Household air pollution and the lung microbiome of healthy adults in Malawi: a cross-sectional study |
| Q89749294 | Human genetics of meningococcal infections |
| Q35626087 | Human lipooligosaccharide IGG that prevents endemic meningococcal disease recognizes an internal lacto-N-neotetraose structure. |
| Q43594925 | Human skin allografts as a useful adjunct in the treatment of purpura fulminans |
| Q36933060 | Hyperproliferation of B cells specific for a weakly immunogenic PorA in a meningococcal vaccine model |
| Q35690291 | IS1301 fingerprint analysis of Neisseria meningitidis strains belonging to the ET-15 clone |
| Q44695129 | Identification by genomic immunization of a pool of DNA vaccine candidates that confer protective immunity in mice against Neisseria meningitidis serogroup B. |
| Q60614684 | Identification of Biomarkers for Differentiation of Hypervirulent Klebsiella pneumoniae from Classical K. pneumoniae |
| Q40353002 | Identification of a new Neisseria meningitidis serogroup C clone from Anhui province, China |
| Q37191264 | Identification of a phage-encoded Ig-binding protein from invasive Neisseria meningitidis |
| Q33274674 | Imaging of disease dynamics during meningococcal sepsis |
| Q38404143 | Immune Homeostatic Macrophages Programmed by the Bacterial Surface Protein NhhA Potentiate Nasopharyngeal Carriage of Neisseria meningitidis |
| Q53565283 | Immune response to conjugated meningococcal C vaccine in pediatric oncology patients. |
| Q33209974 | Immunization of mice with Neisseria meningitidis serogroup B genomic expression libraries elicits functional antibodies and reduces the level of bacteremia in an infant rat infection model. |
| Q46519245 | Immunochemical studies and genetic background of two Neisseria meningitidis isolates expressing unusual capsule polysaccharide antigens with specificities of both serogroup Y and W135. |
| Q46110473 | Immunogenicity and reactogenicity of Infanrix™ when co-administered with meningococcal MenACWY-TT conjugate vaccine in toddlers primed with MenHibrix™ and Pediarix™. |
| Q34290891 | Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age. |
| Q35887131 | Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents. |
| Q37231925 | Immunogenicity of MenACWY-CRM in Korean Military Recruits: Influence of Tetanus-Diphtheria Toxoid Vaccination on the Vaccine Response to MenACWY-CRM. |
| Q42800825 | Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine |
| Q47301746 | Impact of Meningococcal C Conjugate Vaccination Programs with and without catch-up campaigns in adolescents: lessons learned from Bahia, Brazil |
| Q42365570 | Impact of Moderate Temperature Changes on Neisseria meningitidis Adhesion Phenotypes and Proteome. |
| Q27023516 | Importance of circulating antibodies in protection against meningococcal disease |
| Q36950028 | Important role for Toll-like receptor 9 in host defense against meningococcal sepsis |
| Q36916310 | Improved survival of children with sepsis and purpura: effects of age, gender, and era. |
| Q34221093 | In silico studies of outer membrane of Neisseria meningitidis por a: its expression and immunogenic properties |
| Q34916705 | In vivo adaptation and persistence of Neisseria meningitidis within the nasopharyngeal mucosa. |
| Q36177419 | In-silico prediction and deep-DNA sequencing validation indicate phase variation in 115 Neisseria meningitidis genes. |
| Q55003926 | Increase in Neisseria meningitidis serogroup W invasive disease in Canada: 2009-2016. |
| Q33752108 | Independent evolution of the core and accessory gene sets in the genus Neisseria: insights gained from the genome of Neisseria lactamica isolate 020-06. |
| Q41058869 | Induction of the antimicrobial peptide CRAMP in the blood-brain barrier and meninges after meningococcal infection |
| Q28972389 | Infections of People with Complement Deficiencies and Patients Who Have Undergone Splenectomy |
| Q61293682 | Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in vitro and in ex vivo and in vivo models of infection |
| Q33602953 | Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model |
| Q39196108 | Innate immune recognition and inflammation in Neisseria meningitidis infection |
| Q38921081 | Interactions of meningococcal virulence factors with endothelial cells at the human blood-cerebrospinal fluid barrier and their role in pathogenicity |
| Q41093560 | International clone of Neisseria meningitidis serogroup A with tetracycline resistance due to tet(B). |
| Q64135927 | Invasive Meningococcal Disease due to group C N. meningitidis ST11 (cc11): The Tuscany cluster 2015–2016 |
| Q59341059 | Invasive Meningococcal Disease in the Vaccine Era |
| Q64285996 | Invasive Meningococcal Disease: What We Should Know, Before It Comes Back |
| Q33289528 | Invasive meningococcal disease epidemiology and control measures: a framework for evaluation |
| Q44010409 | Invasive meningococcal disease in children in Jerusalem. |
| Q38338388 | Invasive meningococcal disease in the 21st century—an update for the clinician |
| Q35942903 | Invasive serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: persistence of the ST-269 clone since it first emerged in 2003. |
| Q55438652 | Invasive serogroup W Neisseria meningitidis (MenW) in Ontario, Canada shows potential clonal replacement during the period January 1, 2009 to June 30, 2016. |
| Q84010225 | Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine |
| Q36022991 | Ion torrent personal genome machine sequencing for genomic typing of Neisseria meningitidis for rapid determination of multiple layers of typing information |
| Q37349251 | Is the Evolution of Salmonella enterica subsp. enterica Linked to Restriction-Modification Systems? |
| Q73338091 | Isolated septic arthritis: meningococcal infection |
| Q37626017 | Isolation and characterization of Neisseria meningitidis in the vaccine era. Who needs what and when? |
| Q34406242 | Laboratory-based surveillance of Neisseria meningitidis isolates from disease cases in Latin American and Caribbean countries, SIREVA II 2006-2010. |
| Q36391852 | Lessons learned and applied: what the 20th century vaccine experience can teach us about vaccines in the 21st century |
| Q98189280 | Long-term impacts of MenC vaccination campaign in the Salvador, Brazil metropolitan region: A comparison of pre- and post-vaccine periods |
| Q33543163 | Long-term mortality in patients diagnosed with meningococcal disease: a Danish nationwide cohort study |
| Q35598188 | Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood. |
| Q35942471 | Management of meningococcemia |
| Q38028992 | MenACWY-TT vaccine for active immunization against invasive meningococcal disease |
| Q49587387 | MenB-FHbp Meningococcal Group B Vaccine (Trumenba®): A Review in Active Immunization in Individuals Aged ≥ 10 Years |
| Q37159647 | Meningitis caused by Neisseria Meningitidis, Hemophilus Influenzae Type B and Streptococcus Pneumoniae during 2005-2012 in Turkey. A multicenter prospective surveillance study |
| Q30833747 | Meningitis registry of hospitalized cases in children: epidemiological patterns of acute bacterial meningitis throughout a 32-year period |
| Q30249575 | Meningococcal B vaccination: real-world experience and future perspectives. |
| Q44495758 | Meningococcal Disease: The Organism, Clinical Presentation, and Worldwide Epidemiology |
| Q96764321 | Meningococcal Infections in Children and Adolescents: Update and Prevention |
| Q54349722 | Meningococcal Meningitis. |
| Q26752993 | Meningococcal Vaccinations |
| Q37037743 | Meningococcal Vaccine: Which, When and for Whom? |
| Q80512732 | Meningococcal chest pain |
| Q33561983 | Meningococcal disease and climate |
| Q34376170 | Meningococcal disease and the complement system |
| Q35077285 | Meningococcal disease and travel |
| Q89367696 | Meningococcal disease burden and transmission in crowded settings and mass gatherings other than Hajj/Umrah: A systematic review |
| Q38011314 | Meningococcal disease from the public health policy perspective |
| Q35017972 | Meningococcal disease in Asia: an under-recognized public health burden |
| Q58075118 | Meningococcal disease in a kidney transplant recipient with mannose-binding lectin deficiency |
| Q35832179 | Meningococcal disease serogroup C. |
| Q38052545 | Meningococcal disease: changes in epidemiology and prevention |
| Q34460783 | Meningococcal factor H binding protein fHbpd184 polymorphism influences clinical course of meningococcal meningitis |
| Q33274203 | Meningococcal genetic variation mechanisms viewed through comparative analysis of serogroup C strain FAM18. |
| Q35194824 | Meningococcal glycoconjugate vaccines. |
| Q35643952 | Meningococcal immunology |
| Q90491245 | Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile |
| Q81237112 | Meningococcal meningitis |
| Q85032518 | Meningococcal meningitis |
| Q38904656 | Meningococcal pneumonia. |
| Q92968763 | Meningococcal pneumonia: a review |
| Q64101088 | Meningococcal purpura fulminans and severe myocarditis with clinical meningitis but no meningeal inflammation: a case report |
| Q38066532 | Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™). |
| Q37965670 | Meningococcal quadrivalent (serogroups A, C, W135, and Y) conjugate vaccine (Menveo(®)): profile report |
| Q38743826 | Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix™): A review of its immunogenicity, safety, co-administration, and antibody persistence |
| Q34290937 | Meningococcal serogroup B disease in Turkey: a guess or reality? |
| Q27028161 | Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease |
| Q34979682 | Meningococcal vaccine use in college students |
| Q38036064 | Meningococcal vaccine: a new vaccine to combat meningococcal disease in India |
| Q80511370 | Meningococcal vaccines |
| Q37608305 | Meningococcal vaccines: a neglected topic in travel medicine? |
| Q38120493 | Meningococcal vaccines: current issues and future strategies |
| Q43157371 | Meningococcemia Presenting as a Myocardial Infarction |
| Q34155231 | Menveo®): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y. |
| Q34068118 | Metabolism and virulence in Neisseria meningitidis |
| Q44735039 | Modelled evaluation of multi-component meningococcal vaccine (Bexsero®) for the prevention of invasive meningococcal disease in infants and adolescents in the UK. |
| Q46628094 | Modifiable risk factors for invasive meningococcal disease during an Edmonton, Alberta outbreak, 1999-2002. |
| Q90691178 | Modular Polymer Antigens To Optimize Immunity |
| Q36464577 | Molecular analysis of anti-N-propionyl Neisseria meningitidis group B polysaccharide monoclonal antibodies |
| Q54216864 | Molecular characterization of invasive isolates of Neisseria meningitidis in Casablanca-Morocco. |
| Q34201588 | Molecular epidemiological analysis of the changing nature of a meningococcal outbreak following a vaccination campaign |
| Q33229676 | Molecular methods for the detection and characterization of Neisseria meningitidis |
| Q34738737 | Molecular targets in meningococci: efficient routine characterization and optimal outbreak investigation in conjunction with routine surveillance of the meningococcal group B vaccine candidate, fHBP |
| Q30235072 | Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States |
| Q38098068 | Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(®)): a review of its use in primary and booster vaccination |
| Q41426127 | Multilocus variable-number tandem-repeat analysis of Neisseria meningitidis serogroup C in China |
| Q27665568 | N. meningitidis 1681 is a member of the FinO family of RNA chaperones |
| Q37387414 | Natural resistance to Meningococcal Disease related to CFH loci: Meta-analysis of genome-wide association studies |
| Q28749761 | NeMeSys: a biological resource for narrowing the gap between sequence and function in the human pathogen Neisseria meningitidis |
| Q50088760 | Necrotizing fasciitis caused by genogroup × Neisseria meningitidis |
| Q35687415 | Neisseria Base: a comparative genomics database for Neisseria meningitidis |
| Q38183156 | Neisseria meningitidis B vaccines: recent advances and possible immunization policies. |
| Q45141387 | Neisseria meningitidis C:2b:P1.2,5 with decreased susceptibility to penicillin isolated from a patient with meningitis and purpura fulminans |
| Q92822365 | Neisseria meningitidis Induces Pathology-Associated Cellular and Molecular Changes in Trigeminal Schwann Cells |
| Q41995737 | Neisseria meningitidis Serogroup X ST-5799 (ST-22 complex) in Turkey: A Unique Pediatric Case |
| Q99410749 | Neisseria meningitidis carriage and risk factors among teenagers in Suizhou city in China |
| Q37863098 | Neisseria meningitidis endocarditis: a case report and review of the literature |
| Q53252856 | Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. |
| Q92188942 | Neisseria meningitidis has acquired sequences within the capsule locus by horizontal genetic transfer |
| Q28476832 | Neisseria meningitidis has two independent modes of recognizing its human receptor CEACAM1 |
| Q38550405 | Neisseria meningitidis infection: who, when and where? |
| Q35623344 | Neisseria meningitidis serogroup A vaccines: an overview |
| Q39074677 | Neisseria meningitidis strains from patients with invasive meningococcal disease differ in stimulation of cytokine production |
| Q34632986 | Neisseria meningitidis: biology, microbiology, and epidemiology. |
| Q27678569 | Neisseria meningitidisexpresses a single 3-deoxy-d-arabino-heptulosonate 7-phosphate synthase that is inhibited primarily by phenylalanine |
| Q38230370 | Neonatal infection with Neisseria meningitidis: analysis of a 97-year period plus case study |
| Q27488363 | Neurologic Aspects of Infections in International Travelers |
| Q34500860 | Neuronal injury in bacterial meningitis: mechanisms and implications for therapy |
| Q37878480 | New frontiers in meningococcal vaccines |
| Q37690815 | New versus old meningococcal group B vaccines: how the new ones may benefit infants & toddlers |
| Q38328071 | Nonfunctional variant 3 factor H binding proteins as meningococcal vaccine candidates |
| Q35075181 | Novel blocking human IgG directed against the pentapeptide repeat motifs of Neisseria meningitidis Lip/H.8 and Laz lipoproteins |
| Q33761345 | Olfactory nerve--a novel invasion route of Neisseria meningitidis to reach the meninges |
| Q50942520 | On the neisserial vaccine quest: Neisseria Vaccines 2007. |
| Q35683382 | Optimization of Molecular Approaches to Genogroup Neisseria meningitidis Carriage Isolates and Implications for Monitoring the Impact of New Serogroup B Vaccines |
| Q37678717 | Optimizing protection against meningococcal disease |
| Q35887397 | Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvant |
| Q58564772 | Outbreak of Neisseria meningitidis serogroup C outside the meningitis belt-Liberia, 2017: an epidemiological and laboratory investigation |
| Q24643034 | Pathogen recognition and inflammatory signaling in innate immune defenses |
| Q37683101 | Pathogenesis and pathophysiology of bacterial CNS infections |
| Q34290188 | Pathogenicity islands in bacterial pathogenesis |
| Q39026235 | Patterns of structural and sequence variation within isotype lineages of the Neisseria meningitidis transferrin receptor system |
| Q98178429 | Pediatric Hearing Thresholds Post-bacterial Meningitis |
| Q33865408 | Persistence of W135 Neisseria meningitidis carriage in returning Hajj pilgrims: risk for early and late transmission to household contacts |
| Q36689674 | Persistence of antibodies in laboratory staff immunized with quadrivalent meningococcal polysaccharide vaccine |
| Q50963236 | Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations. |
| Q34618580 | Phenotypic and genotypic characteristics of Neisseria meningitidis disease-causing strains in Argentina, 2010. |
| Q54624304 | Pilus-mediated adhesion of Neisseria meningitidis is negatively controlled by the pilus-retraction machinery. |
| Q34128272 | Placental and breast transfer of antibodies after maternal immunization with polysaccharide meningococcal vaccine: a randomized, controlled evaluation |
| Q73355131 | Pneumonia due to Neisseria meningitidis serogroup Y |
| Q24244832 | Polysaccharide vaccines for preventing serogroup A meningococcal meningitis |
| Q33729202 | Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era--United States, 2000-2005 |
| Q36032151 | Population-Based Surveillance of Neisseria meningitidis Antimicrobial Resistance in the United States |
| Q42923051 | Post-marketing study on the safety of a meningococcal group A, C bivalent polysaccharide conjugate vaccine |
| Q42004740 | Postmortem diagnosis of invasive meningococcal disease |
| Q40294861 | Postoperative pulmonary disease associated with haemophilus influenzae and neisseria meningitidis in a diabetic child |
| Q36171021 | Potential capsule switching from serogroup Y to B: The characterization of three such Neisseria meningitidis isolates causing invasive meningococcal disease in Canada |
| Q24200590 | Pre-admission antibiotics for suspected cases of meningococcal disease |
| Q24242705 | Pre-admission antibiotics for suspected cases of meningococcal disease |
| Q24246739 | Pre-admission antibiotics for suspected cases of meningococcal disease |
| Q38726046 | Pre-admission antibiotics for suspected cases of meningococcal disease |
| Q35947795 | Predicted Strain Coverage of a New Meningococcal Multicomponent Vaccine (4CMenB) in Spain: Analysis of the Differences with Other European Countries |
| Q52657380 | Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine. |
| Q35942819 | Prevalence and detailed mapping of the gonococcal genetic island in Neisseria meningitidis |
| Q36282516 | Prevalence of MDR pathogens of bacterial meningitis in Egypt and new synergistic antibiotic combinations |
| Q39145756 | Prevalence of Neisseria meningitidis Carriage with Identification of Serogroups and Genogroups in Professional Soldiers. |
| Q26741972 | Prevention of Meningococcal Infection in the United States: Current Recommendations and Future Considerations |
| Q37403478 | Prevention of meningococcal serogroup C disease by NeisVac-C. |
| Q28080522 | Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals-the example of serogroup B meningococcal infection |
| Q83285159 | Prevention of serogroup B meningococcal disease |
| Q38258647 | Prognostic markers of meningococcal disease in children: recent advances and future challenges |
| Q54255446 | Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development. |
| Q34983894 | Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis |
| Q80238751 | Prospective controlled study of the diagnostic value of skin biopsy in patients with presumed meningococcal disease |
| Q36440358 | Prospects for eradication of meningococcal disease |
| Q24537338 | Prospects for vaccine prevention of meningococcal infection |
| Q35783606 | Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation |
| Q35495765 | Public health management of invasive meningococcal disease in Baden-Wuerttemberg, Germany, 2012: adherence to guidance and estimation of resources required as determined in a survey of local health authorities |
| Q87648371 | Quadrivalent meningococcal (MenACWY-TT) conjugate vaccine or a fourth dose of H. influenzae-N. meningitidis C/Y conjugate vaccine (HibMenCY-TT) is immunogenic in toddlers who previously received three doses of HibMenCY-TT in infancy |
| Q37461347 | Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy |
| Q51853249 | Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006. |
| Q37136539 | Rapidly fatal infections |
| Q90246288 | Recent Advances in the Synthesis of Glycoconjugates for Vaccine Development |
| Q28198677 | Recurrent pericarditis during meningococcal meningitis. 2 case reports |
| Q45057875 | Regulation of Th-1 T cell-dominated immunity to Neisseria meningitidis within the human mucosa |
| Q38531723 | Regulation of capsule in Neisseria meningitidis |
| Q37362174 | Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease |
| Q33905855 | Requirement of NMB0065 for connecting assembly and export of sialic acid capsular polysaccharides in Neisseria meningitidis |
| Q33653905 | Research into practice: acutely ill children |
| Q45726998 | Respiratory syncytial virus infection and invasive meningococcal disease: is there an association? |
| Q33754620 | Respiratory virus infection and risk of invasive meningococcal disease in central Ontario, Canada |
| Q33646965 | Review of meningococcal group B vaccines |
| Q28828692 | Review of meningococcal vaccines with updates on immunization in adults |
| Q37014766 | Rise of the microbes |
| Q36170833 | Risk and prevention of meningococcal disease among education workers: A review |
| Q39872174 | Role of HrpA in biofilm formation of Neisseria meningitidis and regulation of the hrpBAS transcripts |
| Q26995760 | Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease |
| Q50027655 | Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: a phase 3, open-label, randomized study |
| Q41648169 | Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia. |
| Q35778492 | Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation |
| Q80390726 | Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults |
| Q35782650 | Scientific challenges for the quality control and production of group C meningococcal conjugate vaccines |
| Q89559285 | Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine |
| Q35030565 | Sepsis: a frequent, life-threatening syndrome |
| Q50478947 | Sequelae from meningococcal meningitis in children: a critical analysis of dexamethasone therapy. |
| Q37683962 | Serogroup B meningococcal vaccines-an unfinished story |
| Q24290784 | Serogroup W-135 meningococcal disease during the Hajj, 2000 |
| Q33593793 | Serological specificities of murine hybridoma monoclonal antibodies against Neisseria meningitidis serogroups B, C, Y, and W135 and evaluation of their usefulness as serogrouping reagents by indirect whole-cell enzyme-linked immunosorbent assay |
| Q91625944 | Severe meningococcal serogroup W sepsis presenting as myocarditis: A case report and review of literature |
| Q36155973 | Severity of meningococcal infections is related to anthropometrical parameters |
| Q35843926 | Short course intravenous benzylpenicillin treatment of adults with meningococcal disease |
| Q42402468 | Specific PCR Assay for Rapid and Direct Detection of Neisseria meningitidis in Cerebrospinal Fluid Specimens |
| Q42956845 | Specificity of the immune response to a modified group B meningococcal polysaccharide conjugate vaccine |
| Q37106468 | State-based surveillance to determine trends in meningococcal disease |
| Q34889968 | Sterilizing immunity elicited by Neisseria meningitidis carriage shows broader protection than predicted by serum antibody cross-reactivity in CEACAM1-humanized mice. |
| Q24654235 | Structural Basis for the Immunogenic Properties of the Meningococcal Vaccine Candidate LP2086 |
| Q42132567 | Structural basis of the interaction between the putative adhesion-involved and iron-regulated FrpD and FrpC proteins of Neisseria meningitidis |
| Q85065837 | Structural bioinformatics of Neisseria meningitidis LD-carboxypeptidase: implications for substrate binding and specificity |
| Q43455107 | Structural organization of NadADelta(351-405), a recombinant MenB vaccine component, by its physico-chemical characterization at drug substance level |
| Q34661129 | Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody |
| Q27677157 | Structure ofNeisseria meningitidislipoprotein GNA1162 |
| Q100749459 | Study of different routes of immunization using outer membrane vesicles of Neisseria meningitidis B and comparison of two adjuvants |
| Q36326260 | Surveillance of Australian Hajj pilgrims for carriage of potentially pathogenic bacteria: Data from two pilot studies |
| Q33153378 | Surveillance of adverse effects during a vaccination campaign against meningitis C. |
| Q33885257 | Susceptibility of Neisseria meningitidis to 16 antimicrobial agents and characterization of resistance mechanisms affecting some agents |
| Q48030042 | Synthesis of Neisseria meningitidis serogroup W135 capsular oligosaccharides for immunogenicity comparison and vaccine development |
| Q92404815 | Synthetic carbohydrate-based vaccines: challenges and opportunities |
| Q92990753 | Target attainment of cefotaxime in critically ill children with meningococcal septic shock as a model for cefotaxime dosing in severe pediatric sepsis |
| Q36094762 | Targeting of the central nervous system by Listeria monocytogenes |
| Q36851143 | The Burden of Infant Meningococcal Disease in the United States |
| Q90304149 | The Clinical Picture and Severity of Invasive Meningococcal Disease Serogroup W Compared With Other Serogroups in the Netherlands, 2015-2018 |
| Q64108196 | The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology |
| Q38616399 | The Health Burden of Invasive Meningococcal Disease: A Systematic Review |
| Q31069986 | The MisR/MisS two-component regulatory system influences inner core structure and immunotype of lipooligosaccharide in Neisseria meningitidis. |
| Q36139946 | The Phosphocarrier Protein HPr Contributes to Meningococcal Survival during Infection |
| Q37191423 | The RNA chaperone Hfq is involved in stress response and virulence in Neisseria meningitidis and is a pleiotropic regulator of protein expression |
| Q37651436 | The biology of Neisseria adhesins. |
| Q38113259 | The burden and impact of severe and long-term sequelae of meningococcal disease |
| Q39740437 | The burden of hospitalizations for meningococcal infection in Spain (1997-2008). |
| Q43723652 | The case-fatality rate of meningococcal disease in Catalonia, 1990-1997. |
| Q37969481 | The changing and dynamic epidemiology of meningococcal disease |
| Q38743478 | The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004-2014. |
| Q37706585 | The epidemiology of meningococcal disease and the impact of vaccines |
| Q36714648 | The epidemiology of pneumococcal, meningococcal, and Haemophilus disease in the Middle East and North Africa (MENA) region--current status and needs |
| Q88224831 | The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children |
| Q96135488 | The minimal meningococcal ProQ protein has an intrinsic capacity for structure-based global RNA recognition |
| Q44533068 | The polysialic acid-specific O-acetyltransferase OatC from Neisseria meningitidis serogroup C evolved apart from other bacterial sialate O-acetyltransferases |
| Q38989580 | The prevalence, serogroup distribution and risk factors of meningococcal carriage in adolescents and young adults in Turkey. |
| Q33792844 | The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies |
| Q27661691 | The structure of a reduced form of OxyR from Neisseria meningitidis |
| Q29346569 | The zinc-responsive regulon of Neisseria meningitidis comprises 17 genes under control of a Zur element |
| Q36112670 | Thermoregulation of Meningococcal fHbp, an Important Virulence Factor and Vaccine Antigen, Is Mediated by Anti-ribosomal Binding Site Sequences in the Open Reading Frame |
| Q36327065 | Towards an improved serogroup B Neisseria meningitidis vaccine |
| Q36721294 | Transcriptional instability during evolving sepsis may limit biomarker based risk stratification |
| Q36558734 | Transcriptional regulation of the nadA gene in Neisseria meningitidis impacts the prediction of coverage of a multicomponent meningococcal serogroup B vaccine |
| Q33212292 | Translocation and surface expression of lipidated serogroup B capsular Polysaccharide in Neisseria meningitidis. |
| Q45926486 | Travelers' Protection Against Meningococcal Disease: A New Vaccine Option |
| Q36221304 | Trends in meningococcal disease in the United States military, 1971-2010. |
| Q51965590 | Two versus three doses of a meningococcal C conjugate vaccine concomitantly administered with a hexavalent DTaP-IPV-HBV/Hib vaccine in healthy infants. |
| Q36617054 | Underestimation of Invasive Meningococcal Disease in Italy |
| Q50111330 | Underreporting of meningococcal disease incidence in the Netherlands: results from a capture-recapture analysis based on three registration sources with correction for false positive diagnoses |
| Q40092849 | Unraveling Neisseria meningitidis pathogenesis: from functional genomics to experimental models. |
| Q36440863 | Update on prevention of meningococcal disease: focus on tetravalent meningococcal conjugate vaccine |
| Q38631381 | Update on the use of meningococcal serogroup C CRM₁₉₇-conjugate vaccine (Meningitec) against meningitis |
| Q30883698 | Using linked birth, notification, hospital and mortality data to examine false-positive meningococcal disease reporting and adjust disease incidence estimates for children in New South Wales, Australia |
| Q35096463 | Using single-nucleotide polymorphisms to discriminate disease-associated from carried genomes of Neisseria meningitidis |
| Q41932534 | Using the tetravalent meningococcal polysaccharide-protein conjugate vaccine in the prevention of meningococcal disease |
| Q80460188 | Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis |
| Q38218412 | Vaccination in Southeast Asia--reducing meningitis, sepsis and pneumonia with new and existing vaccines. |
| Q35198526 | Vaccination policy in Korean armed forces: current status and future challenge |
| Q26799455 | Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults |
| Q35877401 | Vaccine preventability of meningococcal clone, Greater Aachen Region, Germany |
| Q37514748 | Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future |
| Q36128243 | Vaccines based on the cell surface carbohydrates of pathogenic bacteria |
| Q84089832 | Vaccines targeting serogroup B meningococci |
| Q53303826 | W135 meningococcal carriage in association with the Hajj pilgrimage 2001: the Singapore experience. |
| Q57181124 | WGS analysis of a penicillin-resistant Neisseria meningitidis strain containing a chromosomal ROB-1 β-lactamase gene |
| Q33730806 | Whole genome sequencing reveals within-host genetic changes in paired meningococcal carriage isolates from Ethiopia |
| Q50126137 | Whole-blood incubation with the Neisseria meningitidis lpxL1 mutant induces less pro-inflammatory cytokines than the wild type, and IL-10 reduces the MyD88-dependent cytokines. |
| Q36491155 | Whole-genome comparison of disease and carriage strains provides insights into virulence evolution in Neisseria meningitidis |
| Q64064752 | Whole-genome sequencing and characterization of an antibiotic resistant Neisseria meningitidis B isolate from a military unit in Vietnam |
| Q41971192 | Working mechanism of immunoglobulin A1 (IgA1) protease: cleavage of IgA1 antibody to Neisseria meningitidis PorA requires de novo synthesis of IgA1 Protease |
| Q74800608 | [Acute arthritis-dermatitis syndrome due to Neisseria meningitis] |
| Q90395645 | [Death within Hours] |
| Q89668848 | [Health Technology Assessment of meningococcal B vaccine (Trumenba®) in adolescent in Italy] |
| Q90744080 | [Hemorrhagic skin lesions associated with infections] |
Search more.